Remigromig not checked

EyeBiotech Ltd. · EYE103

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
3 active
4 in total · 2 in the EU
Targets
 

What this is

How it works
An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
How it’s given
“Remigromig is a humanized antibody formulated for intravitreal administration”In the company’s words, NCT06571045 on ClinicalTrials.gov
Tested for
Diabetic Macular Edema (DME) (2 trials), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
Main trialPhase 2/3
“EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.”In the company’s words, NCT06571045 on ClinicalTrials.gov
Other names
EYE103 · Restoret

Other drugs for Diabetic Macular Edema (DME)

All 12 drugs for Diabetic Macular Edema (DME)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting 14 Jul 2026 A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
Phase 2/3Active, not recruiting 11 Jan 2027 A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
Phase 2Recruiting 30 Jun 2028 A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
Phase 1/2Completed 26 Aug 2024 A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Remigromig

Following is part of Solo: you see every change to Remigromig the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in